Logistics management is a key element of operationalizing cell and gene therapy (CAGT) trials. There are unique logistics requirements for autologous cell therapy modalities and allogeneic cell therapies, as well as for in vivo and ex vivo gene therapies and gene editing. Authored by an IQVIA expert, this paper explores key logistics requirements, proposing a holistic and comprehensive approach to logistics management to address the spectrum of complexity across all types of CAGT assets.